211 related articles for article (PubMed ID: 32789513)
1. Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19.
van de Veerdonk FL; Kouijzer IJE; de Nooijer AH; van der Hoeven HG; Maas C; Netea MG; Brüggemann RJM
JAMA Netw Open; 2020 Aug; 3(8):e2017708. PubMed ID: 32789513
[TBL] [Abstract][Full Text] [Related]
2. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications.
Roche JA; Roche R
FASEB J; 2020 Jun; 34(6):7265-7269. PubMed ID: 32359101
[TBL] [Abstract][Full Text] [Related]
3. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
4. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?
Ghahestani SM; Mahmoudi J; Hajebrahimi S; Sioofy-Khojine AB; Salehi-Pourmehr H; Sadeghi-Ghyassi F; Mostafaei H
Iran J Allergy Asthma Immunol; 2020 May; 19(S1):13-17. PubMed ID: 32534506
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
[No Abstract] [Full Text] [Related]
6. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?
Meini S; Zanichelli A; Sbrojavacca R; Iuri F; Roberts AT; Suffritti C; Tascini C
Front Immunol; 2020; 11():2014. PubMed ID: 32849666
[TBL] [Abstract][Full Text] [Related]
7. Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report.
Pecori D; Della Siega P; Sozio E; Barbano E; Mazzoran L; Zanichelli A; Sbrana F; Federico I; Bassi F; Fabris M; Vendramin I; Sbrojavacca R; Tascini C
J Investig Allergol Clin Immunol; 2021 Oct; 31(5):451-452. PubMed ID: 33275101
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
Schoergenhofer C; Jilma B; Stimpfl T; Karolyi M; Zoufaly A
Ann Intern Med; 2020 Oct; 173(8):670-672. PubMed ID: 32422065
[No Abstract] [Full Text] [Related]
9. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.
de Maat S; de Mast Q; Danser AHJ; van de Veerdonk FL; Maas C
Semin Thromb Hemost; 2020 Oct; 46(7):835-837. PubMed ID: 32526773
[No Abstract] [Full Text] [Related]
10. Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Freedberg DE; Conigliaro J; Wang TC; Tracey KJ; Callahan MV; Abrams JA;
Gastroenterology; 2020 Sep; 159(3):1129-1131.e3. PubMed ID: 32446698
[No Abstract] [Full Text] [Related]
11. Boosting the arsenal against COVID-19 through computational drug repurposing.
Ciliberto G; Cardone L
Drug Discov Today; 2020 Jun; 25(6):946-948. PubMed ID: 32304645
[No Abstract] [Full Text] [Related]
12. Dexamethasone nanomedicines for COVID-19.
Lammers T; Sofias AM; van der Meel R; Schiffelers R; Storm G; Tacke F; Koschmieder S; Brümmendorf TH; Kiessling F; Metselaar JM
Nat Nanotechnol; 2020 Aug; 15(8):622-624. PubMed ID: 32747742
[No Abstract] [Full Text] [Related]
13. A role for selenium-dependent GPX1 in SARS-CoV-2 virulence.
Seale LA; Torres DJ; Berry MJ; Pitts MW
Am J Clin Nutr; 2020 Aug; 112(2):447-448. PubMed ID: 32592394
[No Abstract] [Full Text] [Related]
14. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Nicolau LAD; Magalhães PJC; Vale ML
Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
[TBL] [Abstract][Full Text] [Related]
15. Databases for the targeted COVID-19 therapeutics.
Wang Y; Li F; Zhang Y; Zhou Y; Tan Y; Chen Y; Zhu F
Br J Pharmacol; 2020 Nov; 177(21):4999-5001. PubMed ID: 32845521
[No Abstract] [Full Text] [Related]
16. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.
Meng X; Ling Y; Zhang L; Zhang Q; Dong P; Zhu T; Lu H
Biosci Trends; 2020 Jul; 14(3):161-167. PubMed ID: 32536632
[TBL] [Abstract][Full Text] [Related]
17. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign".
Wambier CG; Vaño-Galván S; McCoy J; Gomez-Zubiaur A; Herrera S; Hermosa-Gelbard Á; Moreno-Arrones OM; Jiménez-Gómez N; González-Cantero A; Fonda-Pascual P; Segurado-Miravalles G; Shapiro J; Pérez-García B; Goren A
J Am Acad Dermatol; 2020 Aug; 83(2):680-682. PubMed ID: 32446821
[TBL] [Abstract][Full Text] [Related]
18. BET 2: Hydroxychloroquine in the treatment of COVID-19.
Howard L; Baombe J; Reynard C
Emerg Med J; 2020 Jul; 37(7):451-453. PubMed ID: 32616659
[No Abstract] [Full Text] [Related]
19. [Not Available].
Nau JY
Rev Med Suisse; 2020 Mar; 16(687):606-607. PubMed ID: 32216186
[No Abstract] [Full Text] [Related]
20. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
